Literature DB >> 1516060

High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats.

D Nakae1, H Yoshiji, Y Mizumoto, K Horiguchi, K Shiraiwa, K Tamura, A Denda, Y Konishi.   

Abstract

The carcinogenicities of a choline deficient L-amino acid defined (CDAA) diet and a semipurified choline deficient diet were comparatively examined. A total of 60 male Fischer 344 rats, 6 weeks old, were divided into 5 experimental groups each consisting of 12 rats. Group 1 received the CDAA diet chronically to the end of the 52-week experiment while Group 2 was given the same diet for the first 24 weeks and then a basal diet for the following 28 weeks. Groups 3, 4, and 5 received a choline supplemented L-amino acid defined diet, the semipurified choline deficient diet, and a semipurified choline supplemented diet, respectively, throughout the experimental period. All surviving rats were subjected to complete macroscopic examination at Week 52. Histopathologically diagnosed hepatocellular carcinomas were induced in Group 1 at an incidence of 100%; multiple metastatic nodules were seen in the lungs of one of the animals. Hepatocellular carcinomas were also induced in Group 4 rats at a significantly lower incidence of 20%. No hepatocellular carcinomas were observed in rats in Groups 2, 3, and 4. The results indicate that the CDAA diet exerts more potent carcinogenicity for the livers of rats than does the semipurified choline deficient diet. However, limited exposure for 24 weeks may have not been sufficient for hepatocellular carcinoma induction by the CDAA diet at Week 52 although a high incidence of hyperplastic nodules and slight cirrhosis were evidence of persistent lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 3.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

4.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

Authors:  Alexander Wree; Matthew D McGeough; Carla A Peña; Martin Schlattjan; Hongying Li; Maria Eugenia Inzaugarat; Karen Messer; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2014-05-28       Impact factor: 4.599

5.  Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats.

Authors:  I Sakaida; K Hironaka; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

Review 6.  Dietary choline deficiency causes DNA strand breaks and alters epigenetic marks on DNA and histones.

Authors:  Steven H Zeisel
Journal:  Mutat Res       Date:  2011-10-20       Impact factor: 2.433

Review 7.  Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents.

Authors:  Igor P Pogribny; Ivan Rusyn; Frederick A Beland
Journal:  Environ Mol Mutagen       Date:  2008-01       Impact factor: 3.216

8.  Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Norihisa Nishimura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2013-11-07       Impact factor: 7.527

9.  Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.

Authors:  I A Leclercq; C Sempoux; P Stärkel; Y Horsmans
Journal:  Gut       Date:  2006-02-16       Impact factor: 23.059

Review 10.  Alcohol, cofactors and the genetics of hepatocellular carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan; Shelly C Lu
Journal:  J Gastroenterol Hepatol       Date:  2008-03       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.